Compare Manulife Financial Corporation (MFC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs TransMedics Group Inc — how do they compare? Manulife Financial Corporation trades at $43.84 (market cap $72.68B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Manulife Financial Corporation is far larger — about 23.4× TransMedics Group Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MFC | TMDX | |
|---|---|---|
Market Cap | $72.68B | $3.10B |
Sector | Financials | Technology |
52-Week High | $44.77 | $150.42 |
52-Week Low | $30.06 | $61.99 |
Enterprise Value | $67.84B | $3.49B |
Dividend Yield | 3.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.88, down 0.61% on the day, with a neutral technical signal despite bullish moving averages. The company reported Q2 2026 EPS of $0.79, beating estimates, driven by 21% APE sales growth in Asia. Revenue reached $53.01B in 2025, with net income margin at 11.7%. Recent news highlights AI partnerships with Microsoft and Alibaba Cloud, enhancing operational efficiency.
Outlook is positive with 57% analyst buy ratings and a $51.50 consensus target, though premium valuation (P/E 16.57) and mixed earnings history pose risks. Strengths include robust cash flow and dividend consistency, but investors face headwinds from competitive pressures and regulatory scrutiny in Asian markets.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
